Drug Profile


Alternative Names: ICES-13; Skeletal muscle-derived cells; SMDCs

Latest Information Update: 22 Dec 2015

Price : $50

At a glance

  • Originator Innovacell Biotechnologie GmbH
  • Class Cell therapies; Urologics
  • Mechanism of Action Cell replacements; Cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Stress incontinence

Most Recent Events

  • 20 Apr 2015 Phase-III development is ongoing in Germany, Czech Republic, Poland, Bulgaria, Austria, Italy and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top